Daily tadalafil plus as-needed sildenafil for men whose ED did not respond to PDE5 inhibitors
Official title: Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial
Run by Mansoura University · NCT07391579 · Data updated 2026-11-12
This tests whether taking tadalafil 5 mg every day together with sildenafil 100 mg as needed helps men with erectile dysfunction who did not respond to PDE5 inhibitors alone.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years and up |
| Sex | Men only |
| Enrollment | 500 (estimated) |
| Sponsor | Mansoura University Academic / other |
| Drugs / interventions | radiation |
| Locations | 11 sites (Al Mansurah, Dakahlia Governorate and 10 other locations) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT07391579 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Sexually active adult men with ED for ≥6 months, IIEF-EF score <17, documented non-response to maximum-dose PDE5 inhibitors on at least four occasions, and a stable sexual relationship of ≥6 months are the intended participants.
✕Probably not a fit
Men with penile anatomical deformities or prior penile surgery, active malignancy or severe systemic illness, contraindications to PDE5 inhibitors (including nitrate use or high cardiac risk), or current alternative ED treatments are excluded and unlikely to benefit from this regimen.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 4, randomized interventional study enrolls men with at least six months of erectile dysfunction who failed to respond to maximum-dose PDE5 inhibitors. Participants are randomly assigned to daily tadalafil 5 mg plus on-demand sildenafil 100 mg or daily placebo plus on-demand sildenafil 100 mg, with baseline exams and lab testing before treatment. The main efficacy outcome is change in erectile function measured by the IIEF-EF domain, and safety/tolerability are monitored throughout. The trial is conducted at multiple university urology centers in Egypt.
Why it matters
Potential benefit: If successful, the combination could restore erectile function and improve sexual satisfaction for men who previously did not respond to PDE5 inhibitors alone.
How similar studies have gone: Smaller clinical reports and clinical experience suggest switching or combining PDE5 inhibitors can help some non-responders, but large randomized evidence is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sexually active male. * History of ED for ≥6 months. * Erectile function domain of IIEF-15 score \<17. * Documented failure to respond to PDE-5I \[definition of non-responder patients are patients with ED who don't respond to maximum dose of PDE-5I on ≥4 occasions in spite of accurate timing and good sexual stimulation\]. * Stable sexual relationship ≥ 6 months. Exclusion Criteria: * Penile anatomical deformities or Peyronie's disease. * Pelvic surgery or radiation. * Active malignancy or severe systemic illness. * Previous penile surgery of any kind, such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication or grafting. * Contraindication to PDE5i (High risk cardiac patients, patients on nitrates, hypotension). * Using other treatments for ED e.g., Intra-cavernoasl prostaglandin injection therapy.
Where it's running
-
Urology and Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt Recruiting -
Faculty of medicine, Alexandria University
Alexandria, Egypt Recruiting -
Faculty of medicine, Aswan university
Aswān, Egypt Recruiting -
Faculty of Medicine - Assiut University
Asyut, Egypt Recruiting -
Cairo University, faculty of medicine
Cairo, Egypt Recruiting -
Faculty of medicine, Ain Shams University
Cairo, Egypt Recruiting
Show 5 more locations
-
Faculty of medicine, Azhar University
Cairo, Egypt Recruiting -
Faculty of medicine, october 6 Univeristy
Cairo, Egypt Recruiting -
Faculty of medicine, Luxor university
Luxor, Egypt Recruiting -
faculty of medicine, Minya University
Minya, Egypt Recruiting -
Faculty of medicine, Tanta University
Tanta, Egypt Recruiting
Study contacts
- Study coordinator: Ahmed A Shokeir+2, professor of Urology
- Email: ahmed.shokeir@hotmail.com
- Phone: +201121102929
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intraurethral Alprostadil Paste for Erectile Dysfunction: Dose-Escalation Study
A 12-week, dose-escalation study tests a new alprostadil paste applied inside the urethra to see if it improves erections in men with ED who have not benefited from PDE5 inhibitors.
-
Traditional medicine patterns in men with erectile dysfunction
This project will see which traditional medicine syndrome patterns are most common in men with erectile dysfunction and how those patterns relate to age, health conditions, mood, and habits like smoking and drinking.
-
Tyrosine kinase inhibitors and erectile dysfunction in men with chronic myeloid leukemia
This will see if taking tyrosine kinase inhibitors for chronic myeloid leukemia is linked to erectile dysfunction in adult men.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.